Lorazepam Safety in Patients with Prolonged QT Interval

Mechanism and Safety Profile

• The American College of Cardiology notes that lorazepam can be safely administered to patients with prolonged QT interval as it is not associated with QT prolongation or torsades de pointes 1, 2, 3
• Lorazepam belongs to the benzodiazepine class of medications, which do not appear in any of the guidelines' lists of QT-prolonging medications, according to the American College of Cardiology and Circulation 1, 2, 3
• The American College of Cardiology and the Heart Rhythm Society guidelines for management of patients with ventricular arrhythmias indicate that lorazepam is notably absent from all tables of medications that prolong QT interval 4, 5

Medications to Avoid in Prolonged QT

• The American College of Cardiology recommends that patients with prolonged QT should avoid Class III antiarrhythmic agents (amiodarone, dofetilide, sotalol) 1, 2, 6
• The European Heart Journal suggests that patients with prolonged QT should avoid certain antipsychotics (chlorpromazine, haloperidol, thioridazine) 7
• The European Heart Journal advises that patients with prolonged QT should avoid using multiple QT-prolonging medications concurrently 8

Clinical Considerations

• For patients with prolonged QT interval (>500 ms), the European Heart Journal recommends taking precautions such as avoiding medications explicitly listed as QT-prolonging, maintaining normal electrolyte balance, and monitoring QTc interval when initiating new medications 8
• The European Heart Journal identifies risk factors for torsades de pointes that should prompt extra caution, including female gender, hypokalemia, bradycardia, congestive heart failure, and baseline QT prolongation 7

Monitoring Recommendations

• The European Heart Journal suggests that standard monitoring is sufficient when administering lorazepam to patients with prolonged QT, and no special ECG monitoring is required specifically for lorazepam administration in these patients 8
• The European Heart Journal recommends continuing to monitor underlying QT prolongation as clinically indicated 8